1. INTRODUCTION
Lymphoma, a hematopoietic malignancy with numerous subtypes, can affect people of all ages [1]. Precise and accurate identification of lymphomatous lesions, and measurement of tumor burden, are pivotal for lymphoma prognosis and treatment response. Positron Emission Tomography (PET) / Computed Tomography (CT) [2], [3] is the primary imaging method to assess lymphoma and monitor treatment response. In PET imaging [2], Standardized Uptake Value (SUV) is used to measure 18F-fluorodeoxyglucose (FDG) uptake or glucose metabolism of tumor regions in the PET scan. Lymphoma manifests visually as metabolically hyperactive regions in PET scans. The advantage of combined PET/CT imaging method is that PET is sensitive to identify lymphoma regions whilst CT preserves anatomical structures. Combined PET/CT is therefore useful for lymphoma diagnosis as it helps to identify overall tumour burden and treatment effects. However, segmentation of lymphoma on PET/CT image is still a challenging task because it has various patterns, for example; (1) dispersed throughout the body, (2) outside organs (3) inside organs (4) small delocalized patches. Furthermore, the brain, heart, bowel, kidneys and bladder may also have high SUV responses, which mimics the distinct appearance of lymphoma. These challenges hinder lymphoma segmentation from practical application.